Madrigal (MDGL)
Biotech
Close on Nov 3, 2026 (from our latest article): $396.32
- Market value
- $9.2Bat the Nov 3 closeIncluding convertible preferred and pre-funded warrants: $11.6B
- Revenue growth
- +93%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- −12%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $620Mat Sep 30, 2026
- Worst fall since listing
- −98.4%Jan 28, 2013 to Feb 10, 2016; back to that high in Aug 2025
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
Madrigal’s filings show a development company that funded itself by selling shares, preferred stock and pre-funded warrants, then won US accelerated approval for Rezdiffra in March 2024 and EU conditional approval in August 2025.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 3, 2026
Our View Opinion
Madrigal has the first and best-selling MASH drug and has just reported its first profitable quarter, but it is still a one-drug company whose approvals rest on outcomes trials still to report.
- Median value, end-2030
- $860P10–P90 $487–$1,525
- Chance of beating the hurdle
- 84%
- Implied end-2030 multiple
- 5.4× 2031 salesP25–P75 4.1–7.3× · today 5.3×
Biggest risk: The worst realistic case is a failed F4c trial in 2027 followed by rivals and rising rebates; the tail risk is a failed confirmatory trial in 2028 that puts the approval itself in question.
Nov 3, 2026 · our analysis, not investment advice UPDATED NOV 4
Long-term fundamentals
Annual results for Madrigal, FY2009–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $0.1M in FY2012 to $958M in FY2025.
Free cash flow was positive in 0 of the 17 years shown; FY2025: −$190M.
Margins
Operating margin was −31% in FY2025, vs −276% in FY2024.
Diluted share count
The diluted share count rose 45% from FY2020 to FY2025, to 22M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $958M | — | −31% | −$288M | −$190M | $0.5M | −$190M |
| FY2024 | $180M | — | −276% | −$466M | −$456M | $1M | −$457M |
| FY2023 | $0 | — | — | −$374M | −$324M | $1M | −$326M |
| FY2022 | $0 | — | — | −$295M | −$225M | $0.2M | −$225M |
| FY2021 | $0 | — | — | −$242M | −$184M | $0.2M | −$184M |
| FY2020 | $0 | — | — | −$202M | −$158M | $0.3M | −$158M |
| FY2019 | $0 | — | — | −$84M | −$42M | $0.2M | −$42M |
| FY2018 | $0 | — | — | −$33M | −$26M | $0.0M | −$26M |
| FY2017 | $0 | — | — | −$31M | −$22M | $0.1M | −$22M |
| FY2016 | — | — | — | −$26M | −$18M | $0.0M | −$18M |
| FY2015 | — | — | — | — | −$3M | $0.1M | −$3M |
| FY2014 | — | — | — | — | −$79M | $0.1M | −$79M |
| FY2013 | — | — | — | — | −$77M | $0.8M | −$78M |
| FY2012 | $0.1M | — | −41456% | — | −$54M | $0.5M | −$55M |
| FY2011 | — | — | — | — | −$47M | $0.7M | −$48M |
| FY2010 | — | — | — | — | −$38M | $0.1M | −$38M |
| FY2009 | — | — | — | — | −$27M | $0.5M | −$27M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 22M | $984M | $340M | $98M | — | — |
| FY2024 | 21M | $926M | $118M | $80M | — | — |
| FY2023 | 19M | $634M | $115M | $50M | — | — |
| FY2022 | 17M | $359M | $70M | $32M | — | — |
| FY2021 | 17M | $270M | $0 | $27M | — | — |
| FY2020 | 15M | $284M | — | $21M | — | — |
| FY2019 | — | $439M | — | $23M | — | — |
| FY2018 | — | $484M | — | $13M | — | — |
| FY2017 | — | $192M | — | $3M | — | — |
| FY2016 | — | $19M | — | $8M | — | — |
| FY2015 | — | $0.3M | — | $4M | — | — |
| FY2014 | — | $0.1M | $14M | $7M | — | — |
| FY2013 | — | $48M | $23M | $6M | — | — |
| FY2012 | — | $82M | $4M | $3M | — | $0.0M |
| FY2011 | 47M | $30M | $12M | $3M | — | — |
| FY2010 | 40M | $31M | $12M | $4M | — | — |
| FY2009 | 34M | $44M | — | $5M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 3, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | MDGL | S&P 500 |
|---|---|---|
| 2019 | −19.2% | +31.5% |
| 2020 | +22.0% | +18.4% |
| 2021 | −23.8% | +28.7% |
| 2022 | +242.5% | −18.1% |
| 2023 | −20.3% | +26.3% |
| 2024 | +33.4% | +25.0% |
| 2025 | +88.7% | +17.9% |
| 2026 to date | −31.9% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- TGTX TG Therapeutics Up 5.9%
- CORT Corcept Therapeutics Down 20.1%
- KRYS Krystal Down 11%
- ARWR Arrowhead Down 15.3%
- IOVA Iovance Down 35.4%
- ALNY Alnylam
Show all 17
- TNGX Tango Therapeutics Down 16.4%
- SLS SELLAS Up 156.4%
- VKTX Viking Therapeutics
- GMAB Genmab Up 28.3%
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- MRNA Moderna Down 17.6%
- ORIC ORIC Pharmaceuticals Down 32%
Questions about Madrigal
- How does Madrigal make money?
- Madrigal sells one medicine, Rezdiffra (resmetirom), a once-daily pill for MASH, a fatty-liver disease that scars the liver. In 2025 all $958.4M of its revenue was Rezdiffra net product revenue, and it pays Roche, which discovered the molecule, a tiered single-digit royalty on net sales. More in the Long View →
- What are Madrigal's main growth levers?
- More patients on Rezdiffra (more than 55,850 at Sep 30, 2026), its EU approval in August 2025, a second Phase 3 trial in compensated cirrhosis, and MASH drug candidates licensed since mid-2025 for use in combination with Rezdiffra. More in the Long View →
- Why are Rezdiffra's approvals conditional?
- Its US approval (March 2024) and EU approval (August 2025) are both conditional on outcomes data that confirm the clinical benefit, from Madrigal's MAESTRO-NASH trial. Rezdiffra is approved for adults with moderate to advanced liver scarring, but not cirrhosis. More in the Long View →
- How dependent is Madrigal on a few partners?
- Five unnamed specialty pharmacies and distributors took 90% of its gross product revenue in the first nine months of 2026 together (our calculation). It also relies on outside manufacturers: Evonik for the active ingredient, and UPM and Corden for tablets. More in the Long View →
- What creates Madrigal's funding risk?
- Rezdiffra sales provide cash, but licensing upfronts, receivables and inventory also consume it. Madrigal has funded pipeline licences with cash and carries a secured term loan. More in the Long View →
Disclosure: one or more of our editors own shares of Madrigal (MDGL) as a long-term investment.